MultiVu Video Feed: FDA Approves Extended Dosing of Aranesp(R) to Treat Chemotherapy-Induced Anemia
Posted on: Monday, 27 March 2006, 09:00 CST
NEW YORK, March 27 /PRNewswire/ -- More than two-thirds of cancer patients in the U.S. receiving chemotherapy develop anemia, a low red blood cell count. More than half of chemotherapy patients report that fatigue, a common symptom of anemia, affects their daily lives more than any other side effect of treatment, including nausea, pain and depression.
Anemia treatments have been available for more than a decade, and treatment typically takes more than two hours per visit. Now, the FDA has approved every-three-week dosing of Aranesp, a medication that increases red blood cell counts, for the treatment of chemotherapy-induced anemia. This extended dosing can provide added convenience for patients and less injection-related burden for patients and health care professionals. Aranesp is the only anemia treatment approved for this less frequent dosing.
SATELLITE FEEDS: Monday, March 27th, Monday, March 27th, Tuesday, March 28th, 2006 2006 2006 11:00 AM - 11:15 AM ET 1:00 PM - 1:15 PM ET 3:30 AM - 3:45 AM ET IA 6 IA 6 IA 6 Transponder 15 Transponder 15 Transponder 15 C-Band C-Band C-Band Downlink: 4000 Downlink: 4000 Downlink: 4000 Vertical Vertical Vertical Preview and access this video on Pathfire DMG: 23615 Search within the PR Newswire or MultiVu section by story ID # 23615 or by headline For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com
NEWS: GOOD NEWS FOR 1.3 MILLION CANCER PATIENTS WHO WILL UNDERGO CHEMOTHERAPY THIS YEAR
FORMAT: News Package With Extra Soundbites and B-roll.
ADDITIONAL RESOURCES: Video, contact information and more available at http://www.prnewswire.com/broadcast/23615/consumer.shtml
SOUNDBITES: * Ralph Boccia, MD, Director of Clinical Research, Center for Cancer and Blood Disorders, Bethesda, MD * Danielle Mannix, Patient
B-ROLL INCLUDES:**Doctor patient interaction**Product Shots**Patient lifestyle
VIDEO PROVIDED BY: Amgen FOR TECHNICAL INFORMATION OR HARD COPY, PLEASE CALL: MultiVu Media Relations, 800-653-5313 EXT. 3
Video: http://www.prnewswire.com/broadcast/23615/press.shtml
Amgen
CONTACT: MultiVu Media Relations, 1-800-653-5313 ext. 3
Web site: http://www.multivu.com/
Source: PRNewswire
Related Articles
- Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
- Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients With Anemia Due to Chemotherapy at FDA ODAC Meeting
- FiberNet Telecom Group to Present at Merriman Curhan Ford & Co. Annual IP Video Conference on March 3rd
- Safety of Anti-Anemia Drugs for Chemotherapy Patients Questioned; This Week on Your Cancer Today(TM)
- Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated With Chemotherapy and Chronic Kidney Disease
- Study Explores Use of PROCRIT(R) (Epoetin Alfa) Once Every Two Weeks As Initiation Treatment for Chemotherapy-Related Anemia
- Maxine Gowen, PhD, GSK's SVP, Centre of Excellence for External Drug Discovery, Keynotes at Windhover's ``Pharmaceutical Strategic Outlook'' Conference on March 27-29, 2006 in New York City
- Saints Come Marching Back *** All 2006 Games to Be Played in Louisiana
- Head-to-Head Study of Treatments for Chemotherapy-Related Anemia Published in The Oncologist
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
 |
 |
User Comments (0)
RSS Feeds